Skip to main content
Equibles
ZEAL 238.0000 DKK +0.42%
ZEAL · ZEALAND PHARMA A/S

Use ZEAL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZEAL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
238.0000 DKK +1.0000 (+0.42%) At close · Oct 9
Rebalance outlook locked
Market Cap
15.80B DKK
Shares
66.33M
All webcasts

Earnings call · FY2026 Q1

ZEALAND PHARMA A/S (ZEAL) Q1 2026 Earnings Call

Concluded May 7, 2026
May 7, 2026 0 turns
Period
FY2026 Q1
Runtime
—
Sources
1 artifact
Slides 72

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. slides stays in one workspace.

Petrelentide Phase 3 advancement 39 ADA scientific sessions catalyst 37 Tolerability and GI safety profile 33 Oral and early-stage pipeline 22 Cervidutide Phase 3 results and MASH 21 Roche collaboration economics 13

Management tone

Confident

Net tone +85 · low hedging

Grounding quotes
  • “We are steadily on track to execute our strategy to establish leadership in obesity and metabolic health.”
  • “Taken together, the data demonstrate the potential of petrelentide to address significant unmet needs in chronic weight management by providing a highly tolerable treatment option that supports long-term treatment adherence and achieves double-digit weight loss”
  • “This is a major step forward for the program, for Sinan Pharma and for our collaboration with Ross.”
  • “We are extremely excited with these findings, which taken together demonstrate the potential of cervidotide to broadly improve metabolic health by providing meaningful benefits beyond weight reduction alone.”

Research coverage

1 live source

Open each available source without leaving this research workspace.

Diluted EPS -5.75 DKK/shares

Research materials

Open the source you need; every reader stays inside this workspace.

Presentation 72 pages Company webcastOpen the original investor-relations page
Full-screen source Call document

ZEAL transcript alerts

ZEALAND PHARMA A/S

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →